Adamis Pharmaceuticals Corp (NASDAQ: ADMP) is excited about its rise in stock that stood at 55.7%. Before that, the company stock had declined by 11.50% to settle at $1.00. This “climb,” coupled with its Covid-19 therapy endeavors that seem to be nearing the finish line, continues to inspire hope among investors. The U.S National Institute of Health spoke about Tempol as part of its main highlights, pointing to the substance as a potential Covid-19 therapy.
Adamis push for Tempol’s clearance
In February, Adamis confirmed the FDA’s move to clear Tempol, which happens to be this company’s Investigational New Drug application. NIH suggested Tempol as one of the most promising candidates for the available oral antiviral substances to aid in the treatment of Covid-19.
The study team cares a lot about Tempol’s effectiveness, which is why it wants to embark on more studies. The plan underway is to conduct additional animal studies and also to look for ways to enhance the product in question.
It has been a long journey for the company to get to where it stands currently. One of the major moves was holding a meeting with the FDA, in which case the body gave out a few conditions that needed to be met. For example, the FDA asked the company to make a few additions to the IND. The body specified the manufacturing, controls, chemistry, as well as Clinical aspects.
Tempol and Covid
Tempol might eventually turn out to be a remarkable remedy for handling the Covid -19 pandemic, but it is also crucial to point out the fact that more still needs to be done. For instance, Adamis must seek out funding. The company cites that it remains open to receiving funding from both the government and the non-government entities.
Tempol pulls along with numerous advantages, according to Adamis. Firstly, it proves effective in reducing pro-inflammatory cytokines. The observation in question is based on animal models. The substance might serve as an antioxidant and anti-coagulant as well. All in all, studies show Tempol to work effectively in staging a strong fight against platelet aggregation.